Your browser is no longer supported. Please, upgrade your browser.
Settings
AGIO Agios Pharmaceuticals, Inc. daily Stock Chart
AGIO [NASD]
Agios Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-6.26 Insider Own0.30% Shs Outstand56.34M Perf Week11.11%
Market Cap3.34B Forward P/E- EPS next Y-5.78 Insider Trans-19.55% Shs Float50.64M Perf Month5.50%
Income-342.50M PEG- EPS next Q-1.74 Inst Own- Short Float14.14% Perf Quarter-10.84%
Sales74.20M P/S45.02 EPS this Y10.80% Inst Trans4.50% Short Ratio12.73 Perf Half Y-22.07%
Book/sh11.81 P/B5.02 EPS next Y22.70% ROA-36.20% Target Price88.22 Perf Year-23.96%
Cash/sh10.39 P/C5.71 EPS next 5Y40.00% ROE-44.10% 52W Range41.63 - 99.82 Perf YTD28.58%
Dividend- P/FCF- EPS past 5Y-16.40% ROI- 52W High-40.61% Beta2.35
Dividend %- Quick Ratio6.60 Sales past 5Y29.90% Gross Margin99.10% 52W Low42.42% ATR2.68
Employees482 Current Ratio6.60 Sales Q/Q206.10% Oper. Margin- RSI (14)66.70 Volatility6.37% 4.44%
OptionableYes Debt/Eq0.00 EPS Q/Q12.80% Profit Margin- Rel Volume1.38 Prev Close57.42
ShortableYes LT Debt/Eq0.00 EarningsFeb 14 BMO Payout- Avg Volume562.59K Price59.29
Recom- SMA2010.67% SMA5014.14% SMA200-17.90% Volume774,715 Change3.26%
Feb-15-19Upgrade SVB Leerink Mkt Perform → Outperform $80
Sep-25-18Initiated Leerink Partners Mkt Perform
May-23-18Initiated Citigroup Buy $117
Apr-11-18Reiterated Credit Suisse Outperform $80 → $95
Feb-15-18Reiterated SunTrust Buy $80 → $101
Feb-15-18Reiterated Needham Buy $72 → $86
Sep-15-17Initiated RBC Capital Mkts Outperform $78
Aug-10-17Reiterated Needham Buy $54 → $72
Aug-08-17Reiterated SunTrust Buy $68 → $80
Aug-02-17Upgrade Leerink Partners Mkt Perform → Outperform $80
Jun-26-17Downgrade Janney Buy → Neutral
Jan-17-17Upgrade Oppenheimer Perform → Outperform
Oct-24-16Initiated Needham Buy $60
Jun-13-16Upgrade JP Morgan Neutral → Overweight
May-18-16Reiterated SunTrust Buy $57 → $65
May-18-16Reiterated Sun Trust Rbsn Humphrey Buy $57 → $65
Mar-30-16Initiated Sun Trust Rbsn Humphrey Buy $57
Jan-21-16Initiated Credit Suisse Outperform
Dec-07-15Downgrade Leerink Partners Outperform → Mkt Perform
Nov-09-15Reiterated ROTH Capital Neutral $114 → $75
Feb-15-19 02:25PM  Agios (AGIO) Q4 Earnings Beat, Tibsovo Sales Push Up Stock Zacks
Feb-14-19 12:01PM  Agios Pharmaceuticals Inc (AGIO) Q4 2018 Earnings Conference Call Transcript Motley Fool +6.27%
09:10AM  Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates Zacks
08:10AM  Agios Pharmaceuticals: 4Q Earnings Snapshot Associated Press
07:00AM  Agios Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
Feb-11-19 12:09PM  Agios ex-CEO joins GV as life sciences investment team's co-head American City Business Journals
Feb-07-19 10:31AM  Agios Pharmaceuticals (AGIO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Jan-29-19 01:52PM  Have Insiders Been Selling Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares? Simply Wall St.
Jan-10-19 12:07PM  5 Biotech Stocks That Could Face M&A Next! InvestorPlace
Jan-07-19 07:00AM  Agios Highlights Key 2019 Initiatives to Broaden Potential for Cancer and Rare Genetic Disease Programs to Build Long-Term Value GlobeNewswire +8.70%
Dec-28-18 07:00AM  Agios to Present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 GlobeNewswire
Dec-14-18 12:03PM  Our Take On Agios Pharmaceuticals, Inc.s (NASDAQ:AGIO) CEO Salary Simply Wall St.
Dec-13-18 07:20AM  Market Trends Toward New Normal in DXC Technology, Patterson Companies, Lumentum, DSW, Agios Pharmaceuticals, and Six Flags Entertainment Corporation New Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
03:20AM  Hedge Funds Are Selling Agios Pharmaceuticals Inc (AGIO) Insider Monkey
Dec-12-18 07:00AM  Today's Research Reports on Trending Tickers: Arrowhead Pharmaceuticals and Agios Pharmaceuticals ACCESSWIRE
Dec-08-18 05:36PM  Could These Be the Next 2 Biotech Buyouts? Motley Fool
Dec-07-18 07:00AM  Today's Research Reports on Trending Tickers: Amarin Corporation and Agios Pharmaceuticals ACCESSWIRE -5.37%
Dec-03-18 10:30AM  Agios Presents Updated Data from the Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1 Mutant Positive Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible for Standard Treatment and Myelodysplastic Syndrome (MDS) GlobeNewswire -13.66%
10:15AM  Agios Announces Updated Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Standard Induction and Consolidation Chemotherapy in Newly Diagnosed AML Patients With an IDH Mutation GlobeNewswire
07:00AM  Today's Research Reports on Trending Tickers: Agios Pharmaceuticals and Exelixis ACCESSWIRE
Nov-26-18 07:05AM  Today's Research Reports on Trending Tickers: Agios Pharmaceuticals and Amarin Corporation ACCESSWIRE
Nov-19-18 05:00AM  Edited Transcript of AGIO earnings conference call or presentation 1-Nov-18 12:00pm GMT Thomson Reuters StreetEvents
Nov-16-18 07:00AM  Agios Presents Updated Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma GlobeNewswire
Nov-14-18 06:55AM  Today's Research Reports on Trending Tickers: Exelixis and Agios Pharmaceuticals ACCESSWIRE
Nov-08-18 08:00AM  New Research Coverage Highlights John B. Sanfilippo & Son, Axcelis Technologies, Cogent Communications, Star Bulk Carriers, Agios Pharmaceuticals, and MDC Partners Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
06:00AM  3 Biotech Stocks Poised for Big Rebounds Investopedia
Nov-02-18 01:01PM  Agios (AGIO) Q3 Earnings Beat, Tibsovo Sales Drive Stock Zacks
Nov-01-18 10:41AM  Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Tops Revenue Estimates Zacks +8.64%
09:20AM  Agios to Present Updated Clinical Data at the 2018 ASH Annual Meeting GlobeNewswire
08:22AM  Agios Pharmaceuticals: 3Q Earnings Snapshot Associated Press
08:00AM  Today's Research Reports on Trending Tickers: Agios Pharmaceuticals and Incyte ACCESSWIRE
07:00AM  Agios Reports Third Quarter 2018 Financial Results GlobeNewswire
Oct-19-18 11:44AM  Agios Rides on Tibsovo Approval Amid Reliance on Celgene Zacks
Oct-18-18 07:00AM  Agios to Webcast Conference Call of Third Quarter 2018 Financial Results on November 1, 2018 GlobeNewswire -6.62%
Oct-04-18 07:50AM  New Research Coverage Highlights Camden Property Trust, Agios Pharmaceuticals, Crane, BorgWarner, Cognizant Technology Solutions, and Liberty Broadband Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Oct-01-18 06:35AM  After auspicious run at Agios, biotech exec David Schenkein mulls future American City Business Journals
Sep-19-18 09:37AM  Is Agios Pharmaceuticals Inc (NASDAQ:AGIO) Worth US$71.67 Based On Intrinsic Value? Simply Wall St.
Sep-06-18 08:00AM  Today's Research Reports on Trending Tickers: Agios Pharmaceuticals and Ultragenyx Pharmaceutical ACCESSWIRE
Sep-05-18 10:21AM  Agios (AGIO) Assigns Ex-Celgene Executive to CEO Position Zacks
08:28AM  The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results Benzinga
Sep-04-18 06:33PM  Agios names former Celgene executive Jacqualyn Fouse as next CEO Reuters
06:12PM  Agios names former Celgene executive Jacqualyn Fouse as next CEO Reuters
05:57PM  Agios Announces Chief Executive Officer Succession Plan GlobeNewswire
04:53PM  [$$] Agios Pharmaceuticals Plans to Pump Cash Into R&D The Wall Street Journal
Aug-28-18 07:00AM  Agios to Present at the Citi 13th Annual Biotech Conference Wednesday, September 5, 2018 GlobeNewswire
Aug-17-18 11:49PM  Edited Transcript of AGIO earnings conference call or presentation 2-Aug-18 12:00pm GMT Thomson Reuters StreetEvents
Aug-13-18 09:30AM  Opening Bell, August 13, 2018 CNBC Videos
Aug-03-18 11:55AM  Agios (AGIO) Q2 Loss Narrows, Revenues Surpass Estimates Zacks
Aug-02-18 09:25AM  Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue Estimates Zacks -7.29%
08:47AM  Agios (AGIO) Q2 Loss Narrows, Revenue Beat Estimates Zacks
08:19AM  Agios Pharmaceuticals: 2Q Earnings Snapshot Associated Press
07:00AM  Agios Reports Second Quarter 2018 Financial Results GlobeNewswire
06:00AM  Agios Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Jul-30-18 11:25AM  What's in the Cards for Agios (AGIO) Stock in Q2 Earnings? Zacks
Jul-25-18 08:12AM  Biotech Stock Roundup: Biogen Gains on Q2 Results, Agios Gets FDA Nod For Leukemia Drug Zacks
Jul-23-18 11:26AM  Agios (AGIO) Secures FDA Approval for Leukemia Drug Tibsovo Zacks
07:00AM  Agios to Webcast Conference Call of Second Quarter 2018 Financial Results on August 2, 2018 GlobeNewswire
Jul-20-18 02:46PM  Cambridge's Agios wins FDA approval for second cancer drug American City Business Journals
10:59AM  FDA approves Agios Pharmaceuticals leukemia drug Reuters
10:45AM  FDA Grants Approval of TIBSOVO®, the First Oral, Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation GlobeNewswire
Jun-29-18 07:50AM  Analysis: Positioning to Benefit within Biglari, Trustmark, Allscripts Healthcare Solutions, Agios Pharmaceuticals, Roadrunner Transportation, and OSI Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jun-27-18 11:32AM  Agios Out-Licenses China Rights to Leukemia Drug Tibsovo Zacks
Jun-26-18 08:16AM  BRIEF-Agios And CStone Pharmaceuticals Announce Exclusive Collaboration And License Agreement To Develop And Commercialize Ivosidenib In Greater China Reuters -5.30%
08:00AM  Agios and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Ivosidenib in Greater China GlobeNewswire
Jun-21-18 08:39AM  Benzinga's Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street Benzinga
Jun-20-18 03:54AM  Agios (AGIO) Initiates Phase III Study on PK Deficiency Drug Zacks
Jun-18-18 07:00AM  Agios Announces Initiation of Global Phase 3 Trial (ACTIVATE) of AG-348 in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused GlobeNewswire
Jun-05-18 12:04PM  Agios Pharmaceuticals, Inc.Stock Is an Analyst Darling for Good Reason InvestorPlace
Jun-04-18 09:00AM  New Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Azacitidine Demonstrate Robust Responses and a Well Tolerated Safety Profile in Newly Diagnosed IDHm AML Patients GlobeNewswire
05:43AM  Agios Pharmaceuticals (AGIO) Up 13.4% Since Earnings Report: Can It Continue? Zacks
Jun-02-18 04:05PM  Updated Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1m Relapsed or Refractory AML Continue to Show Durable Responses as a Single Agent GlobeNewswire
Jun-01-18 04:15PM  Agios Presents Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma and Other Solid Tumors GlobeNewswire
08:30AM  Today's Research Reports on Trending Tickers: Tesaro and Agios Pharmaceuticals ACCESSWIRE
08:16AM  Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO Benzinga
May-31-18 04:04PM  Investors Should Own Agios For 'The Next Several Years,' Analyst Says Benzinga
May-30-18 03:17PM  Agios Pharmaceuticals Has Emerged From a 2-Year Base Pattern TheStreet.com
May-24-18 04:18PM  Agios (AGIO) Progressing Well on Pipeline Amid Competition Zacks
May-17-18 07:50AM  Market Trends Toward New Normal in Agios Pharmaceuticals, Corcept Therapeutics, Prestige Brand, Virtu Financial, Eagle Pharmaceuticals, and Century Aluminum Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
May-16-18 05:02PM  Agios to Present New Clinical Data from its IDH Programs at ASCO GlobeNewswire
May-07-18 03:28PM  Agios (AGIO) Q1 Loss Wider than Expected, Revenues Miss Zacks
May-04-18 07:42AM  Agios (AGIO) Q1 Loss Wider than Expected; Sales Miss Zacks
07:09AM  Agios Pharmaceuticals: 1Q Earnings Snapshot Associated Press
07:00AM  Agios Provides Business Update on Discovery Research Strategy and Pipeline, Progress on Clinical Programs, Commercial Launch Preparations and Reports First Quarter 2018 Financial Results at Investor Day GlobeNewswire
Apr-30-18 11:37AM  Is a Beat in the Cards for Agios (AGIO) in Q1 Earnings? Zacks
Apr-27-18 07:00AM  Agios Announces Revised Starting Time of 8:00am ET for Investor Day and First Quarter 2018 Financial Results Webcast on Friday, May 4, 2018 GlobeNewswire
Apr-18-18 09:58AM  Agios' Leukemia Drug Bodes Well for Growth & Strong Pipeline Zacks
Apr-16-18 08:17AM  The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte Zacks
Apr-13-18 09:33AM  Pharma M&A Active This Week: 4 Potential Buyout Targets Zacks
Apr-11-18 07:00AM  Agios to Webcast Investor Day and First Quarter 2018 Financial Results on Friday, May 4, 2018 GlobeNewswire
Apr-10-18 11:23AM  Agios Pharmaceuticals Shares Rise on Buyout Speculation Zacks
Apr-09-18 04:32PM  Why Alcoa, Merck, and Agios Pharmaceuticals Jumped Today Motley Fool +9.26%
Apr-02-18 06:00AM  3 Hot Biotech Stocks Facing Sharp Declines Investopedia -9.97%
Mar-21-18 07:30AM  Wired News Agios Pharmaceuticals Doses First Patient in AG-270 Phase-1 Dose-Escalation Trial in MTAP-Deleted Tumors ACCESSWIRE
Mar-19-18 07:01AM  Agios Announces First Patient Dosed with MAT2A Inhibitor AG-270 in Phase 1 Study in Patients with Advanced Solid Tumors or Lymphoma with an MTAP Deletion GlobeNewswire
Mar-05-18 07:01AM  Agios to Present at the Cowen 38th Annual Healthcare Conference Monday, March 12, 2018 GlobeNewswire
Mar-02-18 07:30AM  Research Report Identifies AutoZone, Highwoods Properties, Virtu Financial, Genocea Biosciences, LGI Homes, and Agios Pharmaceuticals with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Feb-16-18 09:56AM  FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review Zacks
Feb-15-18 11:58AM  FDA Accepts New Drug Application and Grants Priority Review for Ivosidenib in Relapsed or Refractory AML with an IDH1 Mutation GlobeNewswire
11:38AM  Agios (AGIO) Q4 Loss Wider Than Expected, Revenues Slump Y/Y Zacks
03:31AM  Edited Transcript of AGIO earnings conference call or presentation 14-Feb-18 1:00pm GMT Thomson Reuters StreetEvents
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML. The company also develops Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase I clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase I clinical trial for advanced solid tumors; Phase III clinical trials for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination and Phase III clinical trials for newly diagnosed AML patients. In addition, it is developing AG-881, a pan-IDH mutant inhibitor that is in Phase I clinical trial for the treatment of hematologic malignancies; and AG-348, a small molecule potent activator that is in Phase II clinical trials for the treatment of pyruvate kinase deficiency. Agios Pharmaceuticals has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Biller ScottChief Scientific OfficerDec 21Option Exercise2.3420,50047,91924,637Dec 26 04:39 PM
Biller ScottChief Scientific OfficerNov 05Option Exercise9.053,00027,15053,932Nov 07 04:09 PM
Biller ScottChief Scientific OfficerNov 05Sale69.693,000209,07150,932Nov 07 04:09 PM
Biller ScottChief Scientific OfficerOct 05Option Exercise9.053,00027,15053,932Oct 09 04:09 PM
Biller ScottChief Scientific OfficerOct 05Sale69.793,000209,37750,932Oct 09 04:09 PM
MARAGANORE JOHNDirectorSep 12Sale71.7414,1621,015,98222,047Sep 13 04:01 PM
MARAGANORE JOHNDirectorSep 11Sale72.7513,555986,12936,209Sep 13 04:01 PM
Schenkein David PChief Executive OfficerSep 10Option Exercise31.648,730276,21783,849Sep 12 04:12 PM
Biller ScottChief Scientific OfficerSep 05Option Exercise9.053,00027,15060,196Sep 07 04:12 PM
Schenkein David PChief Executive OfficerSep 05Option Exercise3.3275,119249,02875,119Sep 07 04:22 PM
Alenson CarmanPrincipal Accounting OfficerSep 05Option Exercise52.2931216,314464Sep 07 04:18 PM
Biller ScottChief Scientific OfficerSep 05Sale83.073,000249,21557,196Sep 07 04:12 PM
Alenson CarmanPrincipal Accounting OfficerSep 05Sale83.0031225,896152Sep 07 04:18 PM
Bowden ChristopherChief Medical OfficerAug 30Option Exercise35.161,70059,7722,624Aug 31 04:02 PM
Bowden ChristopherChief Medical OfficerAug 30Sale80.031,700136,051924Aug 31 04:02 PM
Bowden ChristopherChief Medical OfficerAug 29Option Exercise35.1630010,5481,224Aug 31 04:02 PM
Bowden ChristopherChief Medical OfficerAug 29Sale80.0030024,000924Aug 31 04:02 PM
Hoerter Steven L.Chief Commercial OfficerAug 24Option Exercise39.762,05081,5082,050Aug 28 04:06 PM
Hoerter Steven L.Chief Commercial OfficerAug 24Sale74.922,050153,5860Aug 28 04:06 PM
Biller ScottChief Scientific OfficerAug 06Option Exercise9.053,00027,15060,196Aug 08 04:14 PM
Biller ScottChief Scientific OfficerAug 06Sale80.113,000240,33357,196Aug 08 04:14 PM
Hoerter Steven L.Chief Commercial OfficerJul 25Option Exercise39.762,05081,5082,050Jul 27 04:01 PM
Hoerter Steven L.Chief Commercial OfficerJul 25Sale84.582,050173,3890Jul 27 04:01 PM
Bowden ChristopherChief Medical OfficerJul 10Option Exercise35.162,00070,3202,924Jul 12 04:14 PM
Bowden ChristopherChief Medical OfficerJul 10Sale86.762,000173,512924Jul 12 04:14 PM
Alenson CarmanPrincipal Accounting OfficerJul 09Option Exercise52.2927214,223272Jul 11 04:23 PM
Alenson CarmanPrincipal Accounting OfficerJul 09Sale84.9427223,1040Jul 11 04:23 PM
Biller ScottChief Scientific OfficerJul 05Option Exercise9.053,00027,15060,196Jul 09 04:08 PM
Biller ScottChief Scientific OfficerJul 05Sale83.503,000250,50357,196Jul 09 04:08 PM
Hoerter Steven L.Chief Commercial OfficerJun 22Option Exercise39.762,05081,5082,050Jun 26 04:02 PM
Hoerter Steven L.Chief Commercial OfficerJun 22Sale97.582,050200,0390Jun 26 04:02 PM
Foster-Cheek Kaye IDirectorJun 14Option Exercise50.739,000456,57011,200Jun 18 04:05 PM
Foster-Cheek Kaye IDirectorJun 14Sale93.559,000841,9262,200Jun 18 04:05 PM
Bowden ChristopherChief Medical OfficerJun 12Option Exercise35.162,00070,3202,881Jun 14 04:23 PM
Bowden ChristopherChief Medical OfficerJun 12Sale92.892,000185,786881Jun 14 04:23 PM
Biller ScottChief Scientific OfficerJun 05Option Exercise9.053,00027,15060,196Jun 07 04:02 PM
Biller ScottChief Scientific OfficerJun 05Sale93.373,000280,10157,196Jun 07 04:02 PM
Schenkein David PChief Executive OfficerJun 01Option Exercise0.4813,0006,28013,000Jun 05 04:10 PM
Schenkein David PChief Executive OfficerJun 01Sale95.3513,0001,239,6080Jun 05 04:10 PM
Schenkein David PChief Executive OfficerMay 30Option Exercise0.3945,62617,67545,626Jun 01 04:08 PM
Schenkein David PChief Executive OfficerMay 30Sale90.0745,6264,109,5340Jun 01 04:08 PM
Biller ScottChief Scientific OfficerMay 23Option Exercise31.6415,177480,20072,373May 29 06:11 AM
Hoerter Steven L.Chief Commercial OfficerMay 23Option Exercise39.762,05081,5082,050May 29 06:14 AM
Schenkein David PChief Executive OfficerMay 23Option Exercise0.3049,37414,93649,374May 29 06:17 AM
Schenkein David PChief Executive OfficerMay 23Sale90.4049,3744,463,5240May 29 06:17 AM
Hoerter Steven L.Chief Commercial OfficerMay 23Sale85.762,050175,8080May 29 06:14 AM
Biller ScottChief Scientific OfficerMay 23Sale90.0015,1771,365,93057,196May 29 06:11 AM
Bowden ChristopherChief Medical OfficerMay 08Option Exercise35.162,00070,3202,881May 10 04:00 PM
Bowden ChristopherChief Medical OfficerMay 08Sale81.382,000162,760881May 10 04:00 PM
Biller ScottChief Scientific OfficerMay 07Option Exercise9.053,00027,15060,196May 08 04:08 PM
Biller ScottChief Scientific OfficerMay 07Sale81.813,000245,43057,196May 08 04:08 PM
Schenkein David PChief Executive OfficerMay 01Option Exercise0.3013,0003,93313,000May 03 04:07 PM
Schenkein David PChief Executive OfficerMay 01Sale83.0413,0001,079,5010May 03 04:07 PM
Hoerter Steven L.Chief Commercial OfficerApr 23Option Exercise39.762,05081,5082,050Apr 25 04:12 PM
Hoerter Steven L.Chief Commercial OfficerApr 23Sale85.952,050176,1980Apr 25 04:12 PM
Bowden ChristopherChief Medical OfficerApr 12Option Exercise35.162,00070,3202,881Apr 16 04:01 PM
Bowden ChristopherChief Medical OfficerApr 12Sale85.102,000170,190881Apr 16 04:01 PM
Biller ScottChief Scientific OfficerApr 05Option Exercise9.053,00027,15060,196Apr 09 04:09 PM
Biller ScottChief Scientific OfficerApr 05Sale75.203,000225,60757,196Apr 09 04:09 PM
Schenkein David PChief Executive OfficerApr 02Option Exercise0.3013,0003,93313,000Apr 04 04:03 PM
Schenkein David PChief Executive OfficerApr 02Sale77.7213,0001,010,3570Apr 04 04:03 PM
Biller ScottChief Scientific OfficerMar 28Option Exercise2.324,1379,61157,196Mar 30 04:18 PM
Hoerter Steven L.Chief Commercial OfficerMar 22Option Exercise39.762,05081,5082,050Mar 26 04:01 PM
Hoerter Steven L.Chief Commercial OfficerMar 22Sale84.652,050173,5330Mar 26 04:01 PM
Foster-Cheek Kaye IDirectorMar 19Option Exercise47.336,800321,8449,000Mar 21 04:04 PM
Foster-Cheek Kaye IDirectorMar 19Sale81.976,800557,3962,200Mar 21 04:04 PM
Scadden DavidDirectorMar 16Buy83.4420016,688571Mar 20 04:43 PM
Bowden ChristopherChief Medical OfficerMar 14Option Exercise35.162,00070,3202,881Mar 16 04:50 PM
Bowden ChristopherChief Medical OfficerMar 14Sale82.332,000164,661881Mar 16 04:50 PM
Biller ScottChief Scientific OfficerMar 05Option Exercise9.053,00027,15056,059Mar 07 04:10 PM
Biller ScottChief Scientific OfficerMar 05Sale83.083,000249,22953,059Mar 07 04:10 PM
Schenkein David PChief Executive OfficerMar 01Option Exercise0.3013,0003,93313,000Mar 05 04:32 PM
Schenkein David PChief Executive OfficerMar 01Sale81.0913,0001,054,2180Mar 05 04:32 PM
Foster-Cheek Kaye IDirectorFeb 26Option Exercise47.332,200104,1262,200Feb 28 04:02 PM
Hoerter Steven L.Chief Commercial OfficerFeb 22Option Exercise39.762,05081,5082,050Feb 26 04:45 PM
Hoerter Steven L.Chief Commercial OfficerFeb 22Sale78.632,050161,1920Feb 26 04:45 PM